曲普瑞林3月剂型治疗特发性中枢性性早熟患儿的临床疗效观察OA

Objective To evaluate the clinical efficacy and safety of the 3-month formulation of triptorelin(triptorelin pamoate)in the treatment of idiopathic central precocious puberty(ICPP)in children.Methods A retrospective analysis was conducted of 49 children with ICPP treated with the 3-month formulation of triptorelin at Xiangya Hospital,Central South University,from May 2023 to September 2025.All patients received at least one injection and completed a 3-month follow-up.The numbers of patients who subsequently completed 6-,9-,and 12-month follow-ups were 42,26,and 11,respectively.Sex hormone levels,growth and development,and the differences between bone age and chronological age(ΔBA-CA)were assessed at 3,6,9,and 12 months after treatment initiation.Results At diagnosis,after the gonadotropin-releasing hormone agonist stimulation test,the peak luteinizing hormone(LH)level was(15.6±5.8)IU/L,the peak follicle-stimulating hormone(FSH)level was(8.5±3.9)IU/L,and the peak LH/FSH ratio was 1.9±0.9.After 3 months of treatment,92%of the children achieved a peak LH<3 IU/L,all children had a peak LH/FSH ratio<0.6,and estradiol or testosterone decreased to prepubertal levels;this suppression was maintained through 12 months without rebound.In girls,uterine length was significantly reduced from baseline at 3,6,9,and 12 months(P<0.0125).In boys,testicular volume was significantly reduced from baseline at each follow-up(P<0.0125).At 3,6,9,and 12 months,ΔBA-CA was significantly decreased compared with baseline in all children(P<0.0125).The incidence of adverse reactions during treatment was low,no treatment discontinuations due to adverse events occurred,and overall tolerability was good.Conclusions The 3-month formulation of triptorelin effectively suppresses the hypothalamic-pituitary-gonadal axis and delays bone age progression in children with ICPP,providing the potential to improve adult height,with a favorable safety profile.